Skip to main content

IGC Pharma Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

IGC$0.20+5.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share data)

June 30, 2024 ($)March 31, 2024 ($)
ASSETS
Current assets:
Cash and cash equivalents1,8241,198
Accounts receivable, net2839
Inventory1,5101,540
Asset held for sale720720
Deposits and advances325208
Total current assets4,4073,705
Non-current assets:
Intangible assets, net1,7201,616
Property, plant, and equipment, net3,5863,695
Claims and advances688688
Operating lease asset193198
Total non-current assets6,1876,197
Total assets10,5949,902
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable771773
Accrued liabilities and others1,7181,567
Total current liabilities2,4892,340
Non-current liabilities:
Long-term loans136137
Other liabilities2020
Operating lease liability6984
Total non-current liabilities225241
Total liabilities2,7142,581
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of June 30, 2024, and March 31, 2024.
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 75,636,419 and 66,691,195 shares issued and outstanding as of June 30, 2024, and March 31, 2024, respectively.127,349124,409
Accumulated other comprehensive loss(3,426)(3,423)
Accumulated deficit(116,043)(113,665)
Total stockholders’ equity7,8807,321
Total liabilities and stockholders’ equity10,5949,902

| June 30, 2024, Form 10-Q

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.